Literature DB >> 30078438

Consider Changing the Horse for Your CAR-T?

Matthew H Wilson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30078438      PMCID： PMC6094485          DOI： 10.1016/j.ymthe.2018.06.018

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

1.  Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.

Authors:  Yozo Nakazawa; Leslie E Huye; Gianpietro Dotti; Aaron E Foster; Juan F Vera; Pallavi R Manuri; Carl H June; Cliona M Rooney; Matthew H Wilson
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

2.  Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera.

Authors:  M J Fraser; T Ciszczon; T Elick; C Bauser
Journal:  Insect Mol Biol       Date:  1996-05       Impact factor: 3.585

3.  Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells.

Authors:  Z Ivics; P B Hackett; R H Plasterk; Z Izsvák
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

4.  PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.

Authors:  David C Bishop; Ning Xu; Benjamin Tse; Tracey A O'Brien; David J Gottlieb; Alla Dolnikov; Kenneth P Micklethwaite
Journal:  Mol Ther       Date:  2018-06-01       Impact factor: 11.454

5.  Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Authors:  Partow Kebriaei; Harjeet Singh; M Helen Huls; Matthew J Figliola; Roland Bassett; Simon Olivares; Bipulendu Jena; Margaret J Dawson; Pappanaicken R Kumaresan; Shihuang Su; Sourindra Maiti; Jianliang Dai; Branden Moriarity; Marie-Andrée Forget; Vladimir Senyukov; Aaron Orozco; Tingting Liu; Jessica McCarty; Rineka N Jackson; Judy S Moyes; Gabriela Rondon; Muzaffar Qazilbash; Stefan Ciurea; Amin Alousi; Yago Nieto; Katy Rezvani; David Marin; Uday Popat; Chitra Hosing; Elizabeth J Shpall; Hagop Kantarjian; Michael Keating; William Wierda; Kim Anh Do; David A Largaespada; Dean A Lee; Perry B Hackett; Richard E Champlin; Laurence J N Cooper
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

6.  Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice.

Authors:  Sheng Ding; Xiaohui Wu; Gang Li; Min Han; Yuan Zhuang; Tian Xu
Journal:  Cell       Date:  2005-08-12       Impact factor: 41.582

7.  Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.

Authors:  Alla Dolnikov; Sylvie Shen; Guy Klamer; Swapna Joshi; Ning Xu; Lu Yang; Kenneth Micklethwaite; Tracey A O'Brien
Journal:  Exp Hematol       Date:  2015-09-16       Impact factor: 3.084

8.  piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Authors:  Pallavi V Raja Manuri; Matthew H Wilson; Sourindra N Maiti; Tiejuan Mi; Harjeet Singh; Simon Olivares; Margaret J Dawson; Helen Huls; Dean A Lee; Pulivarthi H Rao; Joseph M Kaminski; Yozo Nakazawa; Stephen Gottschalk; Partow Kebriaei; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

Review 9.  piggyBac-ing models and new therapeutic strategies.

Authors:  Lauren E Woodard; Matthew H Wilson
Journal:  Trends Biotechnol       Date:  2015-07-23       Impact factor: 19.536

10.  The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Authors:  Michael Hudecek; Daniel Sommermeyer; Paula L Kosasih; Anne Silva-Benedict; Lingfeng Liu; Christoph Rader; Michael C Jensen; Stanley R Riddell
Journal:  Cancer Immunol Res       Date:  2014-09-11       Impact factor: 11.151
View more
  2 in total

1.  CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.

Authors:  Yu Yang Ng; Zhicheng Du; Xi Zhang; Wee Joo Chng; Shu Wang
Journal:  Cancer Gene Ther       Date:  2021-09-01       Impact factor: 5.987

2.  Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells.

Authors:  Johan C K Tay; Junjian Wang; Zhicheng Du; Yu Yang Ng; Zhendong Li; Yuefang Ren; Chang Zhang; Jianqing Zhu; Xue Hu Xu; Shu Wang
Journal:  Mol Ther Methods Clin Dev       Date:  2021-03-03       Impact factor: 6.698
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.